SCHEDULE: Vanguard Group Adjusts Evolent Health Reporting

The Vanguard Group filed an amended Schedule 13G, reporting zero beneficial ownership in Evolent Health Inc. following an internal reporting realignment.

Summary

• The Vanguard Group filed an Amendment No. 8 to Schedule 13G concerning Evolent Health Inc. Common Stock.
• As of the event date 03/13/2026, The Vanguard Group reports 0.00 shares beneficially owned, representing 0% of the class.
• This change in reported ownership is a result of an internal realignment within The Vanguard Group, Inc. on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of Vanguard will now report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as neutral for Evolent Health, as it primarily reflects an internal reporting change by Vanguard rather than a strategic investment decision regarding the issuer's fundamentals or prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Evolent Health Inc.'s future performance or operations. It solely addresses a change in beneficial ownership reporting by The Vanguard Group.

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment.
• Certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc.
• These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that institutional investors like Vanguard frequently adjust their internal reporting structures or reallocate holdings among various internal entities. This can lead to changes in reported beneficial ownership without necessarily indicating a change in the overall investment strategy or sentiment by the broader institution towards the issuer. This realignment reflects a shift in reporting methodology rather than a strategic divestment from Evolent Health by the entire Vanguard ecosystem.

Stakeholder Impact

• Shareholders of Evolent Health: May initially perceive a major institutional investor has divested, but understanding the internal realignment clarifies that the underlying investment strategy by Vanguard's broader entities may remain unchanged.
• The Vanguard Group: Its internal realignment impacts its reporting structure, with subsidiaries now filing separately, ensuring compliance with SEC regulations.

Key Dates

Keywords

Evolent Health, Vanguard Group, Schedule 13G, beneficial ownership, institutional ownership, common stock, investment adviser, SEC filing